<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056260</url>
  </required_header>
  <id_info>
    <org_study_id>SDR-01</org_study_id>
    <nct_id>NCT04056260</nct_id>
  </id_info>
  <brief_title>ICG-NIR Guided Lymph Node Dissection in Gastric Cancer</brief_title>
  <official_title>Oncologic Safety of Sentinel Lymph Node-guided Lymph Node Dissection Using ICG-NIR Laparoscopy in Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ho Seok Seo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the survival rate of patients with gastric cancer has increased, there has been a growing
      interest in interventions that improve postoperative quality of life. Therefore minimally
      invasive surgery or endoscopic resection has been performed much more frequently. However,
      adequate lymph node dissection is important as well. The aim of the study is to identify the
      feasibility of indocyanine green - near infra-red (ICG-NIR) guided sentinel lymph node
      dissection for the treatment of gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity and specificity</measure>
    <time_frame>1 month</time_frame>
    <description>sensitivity and specificity of ICG-NIR guided lymph node dissection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">219</enrollment>
  <condition>Stomach Neoplasm</condition>
  <arm_group>
    <arm_group_label>ICG injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ICG 0.5mg/ml x 0.5ml x 4 sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICG-NIR guided surgery</intervention_name>
    <description>ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy</description>
    <arm_group_label>ICG injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dignosed gastric adenocarcinoma

          -  tumor: size 4cm or smaller

          -  depth of invasion: mucosa, submucosa, proper muscle

          -  candidates of laparoscopic radical gastrectomy

          -  informed consent

        Exclusion Criteria:

          -  metachronous malignancy

          -  number of tumors: 2 or more

          -  remnant gastric cancer

          -  indication for endoscopic resection

          -  history of chemotherapy or radiation therapy

          -  pregnancy

          -  allergy to ICG

          -  metastatic gastric cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Ho Seok Seo</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

